Supplier's Corner

Zanthin XP-3 Astaxanthin

March 19, 2012

Valensa has launched a new astaxanthin formulation designed to provide optimal absorption at lower use levels. Called Zanthin XP-3 astaxanthin, the new product combines Valensa’s Zanthin natural astaxanthin with a supercritical extract perilla seed oil, O2B peroxidation blocker stabilization system and sunflower-based phospholipids in a synergistic formulation that enhances the human body’s absorption of the astaxanthin. Rather than adopt a strategy of large Astaxanthin doses to ensure the optimal 2 mg to 4 mg intake levels research has shown the body can utilize, Zanthin XP-3 typically makes the Astaxanthin 90% available across the board. For further information: www.valensa.com
  • Oral Solid Dosage Outsourcing: Trends & Challenges

    Oral Solid Dosage Outsourcing: Trends & Challenges

    Tim Wright, Editor, Contract Pharma||March 1, 2017
    Despite the increasing number of biologics, oral solids remain the dominant dosage form in the pharmaceutical market.

  • Skeleton Crew: Solutions for Bone Health

    Skeleton Crew: Solutions for Bone Health

    Lisa Schofield, Contributing Writer||March 1, 2017
    Products that can help aging populations stay active and independent will be in a strong market position.

  • Formulation Strategies for  Aging Consumers

    Formulation Strategies for Aging Consumers

    Stephen Tindal, Director, Science and Technology, Catalent Pharma Solutions||March 1, 2017
    Convenience, flavor and novel combinations of ingredients can help offer better product experiences.